Among those who connected salary increases to swapping out employers, 75% saw pay rise by at least 6%, and the most often cited increase was 10%, according to the just-released BioSpace salary report.

Original title: “Changing Employers Can Boost Salaries Higher Than Staying Put: BioSpace Report”

BioSpace's 2026 U.S. Life Sciences Salary Report delivers a comprehensive look at how salaries, bonuses and benefits evolved over the past year amid ongoing economic pressure and workforce recalibration. It uncovers not just what people are earning, but how they’re thinking about compensation, career moves and total rewards in 2026.

Original title: “Report: 2026 U.S. Life Sciences Salary Report”

Looking for a clinical job? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.

Original title: “11 Companies Hiring Clinical Professionals Now”

Every biopharma R&D and investment decision could be guided by connected intelligence. Join us to hear firsthand how agentic workflows and enterprise-scale data are helping drug developers move faster from molecule to market with greater confidence.

Original title: “Webinar: The Agentic Test: Can AI Actually Accelerate Drug Development and Break Down Silos Across Pharma?”

Constructing the cGMP facility will increase availability of actinium-225, a nuclear material central to radiopharmaceutical programs at AstraZeneca, Bristol Myers Squibb, Eli Lilly and Novartis.

Original title: “TerraPower Commits $450M to Build Radioisotope Production Plant”

As part of a larger review, analyst Leonid Timashev identified 13 companies that could see deal interest as well as more than half a dozen poised to be potential buyers.

Original title: “RBC: Revolution, Xenon, Arrowhead among top takeover targets”

The top 10 stocks in the S&P 500 make up almost 40% of the index's weight. If SpaceX, OpenAI, and Anthropic join the index, that could hit 50%. In today's market, where tech giants dominate the S&P 500, mega IPOs could intensify the risks derived from heavy concentration. "More than $40 of every $100 invested flows into just 10 companies, creating a feedback loop where passive inflows disproportionately support the largest stocks, increasing their weights and reinforcing performance leadership regardless of fundamentals," RBC Wealth Management said,

Original title: “Mega-IPOs from SpaceX and others could intensify already 'dangerous' concentration risk in the stock market”

Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million payment.

Original title: “Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights”

Track 2026 IPO prospects with Kalshi odds for SpaceX, OpenAI, Discord, Kraken & more—plus IPO ETF ideas Mar. 18, 2026 10:57 AM ETAPD, IPO, IPOS, SPACE, DSCD, CBRS, OPENAI, ANTHROBy: Jason Capul, SA News Editor

Original title: “2026 IPO watchlist: OpenAI, SpaceX, Anthropic, Discord, Kraken, and more | Seeking Alpha”

Deal covers up to five candidates including SB36 as company expands global pipeline

Original title: “Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars”

Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead program CBX-250.

Original title: “Crossbow raises $77M for new cancer immunotherapies”

The funding, which ranks as one of the largest of its kind for a China-based drug startup, will support a portfolio of multifaceted antibodies the company believes to be advances over existing treatments.

Original title: “Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers”

Excalipoint Therapeutics will use its seed money to advance a pipeline of cancer therapies, including a tri-specific antibody for small cell lung cancer and neuroendocrine tumors.

Original title: “Lilly-Backed China Startup Debuts With $68.7M Seed to Advance Next-Gen T Cell Engagers”

Alongside R1 Therapeutics, Mestag Therapeutics and iDEL Therapeutics also brought in money on Tuesday, helping to push their respective cancer portfolios forward.

Original title: “R1 Leads Busy Fundraising Day With $77.5M Series A Raise for Kidney Disease”

While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established itself as the clear leader in the obesity market, in the process capturing investors’ attention and enthusiasm.

Original title: “J&J Reigns as Top Pharma by Revenue While Lilly Leapfrogs on Strong Obesity Sales”

The major pharmas are loaded up with trillions in firepower—but are sticking to mid-cap deals. One expert says it might be time to think outside the box and shake up the industry with some consolidation.

Original title: “In Tight Deal Environment, Pharma May Need To Think Big”

According to a news release, Oculis officials hope to forward product candidates to address areas of significant medical needs, including diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma, affecting growing patient populations. According to a news release, Oculis officials hope to forward product candidates to address areas of significant medical needs, including diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma, affecting growing patient populations. ... Oculis, SA and European Biotech Acquisition Corp. OCS-05 is a serum-glucocorticoid kinase 2 (SGK-2) activator, in development as a potential disease-modifying neuroprotective agent to address neurological damage to the optic nerve. OCS-05 is initially in development as a potential therapeutic for acute optic neuritis, or AON, a rare disease with high unmet need as currently, there is no approved treatment for AON. “EBAC was formed to invest in the untapped potential in the European biotechnology sector and has screened over 100 European biotechnology companies,” he said in the news release. “Oculis is a prime example of what we set out to invest in, with great innovation, a well thought out strategy and an experienced management team to bring promising therapies to market for patients suffering from eye disease.” OCS-01 was purposefully designed to enable a potential breakthrough approach in the treatment of retinal diseases; a topical, non-invasive approach. Current therapies require intra-ocular injections. Effective topical therapies would complement the existing approaches by adding an option with improved patient comfort, safety, accessibility, cost and allowing individualized dosing.

Original title: “Oculis SA, European Biotech Acquisition Corp. announce business combination agreement | Ophthalmology Times - Clinical Insights for Eye Specialists”

Track new IPO candidates in our pharma and biotech IPOs of 2026 listing across oncology, immunology and emerging drug discovery platforms. Register for this webinar to learn how to operationalize diverse clinical trials through inclusive design, community partnership and patient-centered engagement. Agomab Therapeutics raised about $200 million in its February 2026 Nasdaq IPO after pricing 12.5 million American Depositary Shares (ADS) at $16 each under the ticker AGMB. The clinical-stage biotech is developing therapies aimed at fibrotic diseases linked to TGFβ signaling. Biotech IPO activity began to reappear in 2026, with several clinical-stage companies entering public markets after a more cautious funding environment in recent years. Many of these offerings focus on therapies for cancer, immunology and other serious diseases. MapLight Therapeutics raised $372.5 million in a Series D financing to advance clinical trials of a muscarinic receptor agonist program for schizophrenia and Alzheimer’s disease psychosis. AI-focused drug discovery company Isomorphic Labs secured $600 million to develop its AI drug design platform and advance therapeutic programs toward the clinic. Eikon Therapeutics also raised more than $350 million in a Series D financing in 2025 to expand its oncology pipeline ahead of a planned public listing. This blog tracks the major biotech IPOs of 2026, showcasing companies going public and the therapies and technologies they are bringing to the biotech landscape. Lead candidate ontunisertib is being studied for fibrostenosing Crohn’s disease, while a second program, AGMB-447, is an inhaled ALK5 inhibitor in development for idiopathic pulmonary fibrosis. Aktis Oncology closed an upsized IPO in January 2026, raising about $365 million in gross proceeds after pricing 17.65 million shares at $18.00 each and the full exercise of the underwriters’ option for additional shares. The Boston-based, clinical-stage biotech is developing targeted radiopharmaceuticals using a proprietary miniprotein platform designed to deliver alpha-emitting isotopes directly to tumor-associated targets.

Original title: “Pharma and Biotech IPOs of 2026: A Running List - Xtalks”

This webinar introduces the DIA Artificial Intelligence Consortium, a neutral, public‑private partnership that convenes regulators, biopharmaceutical companies, academia, and technology providers, including FDA, Health Canada, MHRA, PMDA, IQVIA, Gilead, Otsuka, BeOne Medicines, Beth Israel Deaconess Medical Center–Yale School of Medicine, and others.

Original title: “Webinar: Operationalizing AI in Drug Development: Inside DIA’s Global AI Consortium”

The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat to Pfizer’s fast-selling bladder cancer drug.

Original title: “Bicycle to lay off 30% of staff, pivot away from Padcev challenger”